Relationship between CYP2E1 Gene Polymorphism and Anti-tuberculosis Drug-induced Liver Injury

Authors

  • Donglin Zhu Department of Laboratory Medicine, The Third Affiliated Hospital of Sun Yat-sen University
  • Yun Xi Department of Laboratory Medicine, The Third Affiliated Hospital of Sun Yat-sen University,
  • Jieming Dong Department of Laboratory Medicine, The Third Affiliated Hospital of Sun Yat-sen University
  • Fanhua Huang Department of Laboratory Medicine, The Third Affiliated Hospital of Sun Yat-sen University
  • Changzhi Xu Department of Laboratory Medicine, The Third Affiliated Hospital of Sun Yat-sen University
  • Gang Xiao Department of Laboratory Medicine, The Third Affiliated Hospital of Southern China Medical University

DOI:

https://doi.org/10.30564/jams.v1i4.289

Abstract

 Objective: To investigate the relationship between cytochrome P450 E1 (CYP2E1) gene polymorphisms and susceptibility to anti-tuberculosis drug-induced liver damage (ATDLI) in tuberculosis patients in the Chinese Han nationality. Methods: A retrospective analysis was performed on 360 patients with tuberculosis who had liver damage after tuberculosis treatment (case group) and 360 patients with tuberculosis who did not develop liver injury after treatment (control group). MassARRAY were used to detect CYP2E1 gene polymorphisms. Results: In a total of 8 tagged SNP loci selected, the rs8192773 locus failed to pass the test, and therefore, it is not included in subsequent analysis. At the remaining seven SNP sites, the difference in alleles was not statistically significant between the case group and the control group, suggesting that these sites may not be related to liver damage caused by anti-tuberculosis drugs. Three monomer domains were found in the seven tags SNP loci mentioned above. However, it was found that these haplotypes are not closely related to anti-tuberculosis drug-induced liver damage. Conclusion: The CYP2E1 gene polymorphism in the Chinese Han nationality is not related to the occurrence of anti-tuberculosis drug-induced liver injury.

Keywords:

CYP2E1, MassARRAY, Tuberculosis, Liver injury, Genetic polymorphism

References

[1] Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to anti-tuberculosis drug-induced hepatitis[J]. Hepatology, 2003, 37(6):924-930.

[2] Gupta VH, Amarapurkar DN, Singh M, et al. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India[J]. J Gastroenterol Hepatol, 2013, 28(8):1368-1374.

[3] Jiang O, Zhou R, Wu D, et al. CYP2E1 polymorphisms and colorectal cancer risk: a HuGE systematic review and meta-analysis[J]. Tumour Biol, 2013, 34(2):1215-1224.

[4] Munaka M, Kohshi K, Kawamoto T, et a1. Genetic polymorphism of tobacco and alcohol-related metabolizing enzymes and risk of hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2003, 129(6): 355-360.

[5] He X., Feng S. Role of metabolic enzymes P450 (CYP) on activating procarcinogen and their polymorphisms on the risk of cancers[J]. Current Drug Metabolism, 2015, 16(10):850-863.

[6] N Ben Fredj, R Gam, E Kerkni, et al. Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients[J]. The Pharmacogenomics Journal, 2017, 17(4): 372-377.

[7] Dyah Aryani Perwitasari, Jarir Atthobari, Bob Wilffert. Pharmacogenetics of isoniazid-induced hepatotoxicity[J]. Drug Metabolism Reviews, 2015, 47(2): 222-228.

[8] Roy B, Ghosh SK, Sutradhar D, et al. Predisposition of antituberculosis drug induced hepatotoxicity by cytochrome P450 2E1 genotype and haplotype in pediatric patients[J]. J Gastroenterol Hepatol. 2006, 21(4):784-786.

[9] Chamorro JG, Castagnino JP, Aidar O, et al. Effect of gene-gene and gene-environment interactions associated with antituberculosis drug-induced hepatotoxicity[J].Pharmacogenet Genomics, 2017, 27(10):363-371.

[10] Bose PD, Sarma MP, Medhi S, et al. Role ofpolymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis[J]. J Gastroenterol Hepatol, 2011, 26(2):312-318.

[11] Yi-Shin Huang, Herng-Der Chern, Wei-Juin Su, et al. Polymorphism of the N-Acetyltransferase 2 Gene as a Susceptibility Risk Factor for Antituberculosis Drug–Induced Hepatitis[J]. Hepatology, 2002, 35(4):883-889.

[12] Nicolas Vuilleumier, Michel F, Rossier, Alberto Chiappe, et al. CYP2E1 genotype and isoniazid- induced hepatotoxicity in patients treated for latent tuberculosis[J]. Eur J Clin Pharmacol, 2006, 62(6): 423-429.

[13] T Wang, HT Yu, W Wang, et al. Genetic Polymorphisms of Cytochrome P450 and Glutathione S-transferase Associated with Antituberculosis Drug-induced Hepatotoxicity in Chinese Tuberculosis Patients[J]. J Int Med Res, 2010, 38(3):977-986.

[14] Soukaina G, Ilham R, Fatima ZL et al. Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population[J]. BMC Genet, 2014, 15:156.

[15] Teixeira RL, Morato RG, Cabello PH, et al. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients[J]. Mem Inst Oswaldo Cruz, 2011, 106(6):716-724.

Downloads

Issue

Vol. 1 , Iss. 4 (November 2018)

Article Type

Research Article

License

Copyright and Licensing

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

Journal of Advances in Medicine Science publishes accepted manuscripts under Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). Authors who submit their papers for publication by Journal of Advances in Medicine Science agree to have the CC BY-NC 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for non-commercial use. As long as you follow the license terms and original source is properly cited, anyone may copy, redistribute the material in any medium or format, remix, transform, and build upon the material.

License Policy for Reuse of Third-Party Materials

If a manuscript submitted to the journal contains the materials which are held in copyright by a third-party, authors are responsible for obtaining permissions from the copyright holder to reuse or republish any previously published figures, illustrations, charts, tables, photographs, and text excerpts, etc. When submitting a manuscript, official written proof of permission must be provided and clearly stated in the cover letter.
The editorial office of the journal has the right to reject/retract articles that reuse third-party materials without permission.

Journal Policies on Data Sharing

We encourage authors to share articles published in our journal to other data platforms, but only if it is noted that it has been published in this journal.